The Anti-Diabetes Drugs market in Croatia has been showing steady growth over the past few years.
Customer preferences: Croatia has a rapidly aging population, which has led to an increase in the number of people suffering from diabetes. As a result, there has been a growing demand for anti-diabetes drugs in the country. Additionally, there has been a shift towards healthier lifestyles and an increased awareness of the importance of managing diabetes through medication and lifestyle changes.
Trends in the market: The market for anti-diabetes drugs in Croatia is dominated by big pharma companies, with Novo Nordisk being the market leader. However, there has been a growing trend towards the use of generic drugs, which are more affordable for patients. This has led to increased competition in the market, with more generic drug manufacturers entering the market.
Local special circumstances: Croatia has a publicly funded healthcare system, which means that the government plays a significant role in the provision of healthcare services. This has led to a focus on cost-effectiveness in the provision of healthcare services, including the use of generic drugs. Additionally, there has been a growing trend towards the use of telemedicine in the management of diabetes, which has been encouraged by the government.
Underlying macroeconomic factors: Croatia has a relatively small economy, which has been affected by the COVID-19 pandemic. However, the government has implemented measures to support the healthcare sector, including the provision of funding for the purchase of medical equipment and the recruitment of additional healthcare workers. Additionally, Croatia is a member of the European Union, which has provided funding for the development of healthcare infrastructure in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
